Literature DB >> 26548428

The Minimum Clinically Important Difference in the Repeatable Battery for the Assessment of Neuropsychological Status.

Rachel Phillips1, Gao Qi2,3, Simon Lowes Collinson2,4, Audrey Ling2,3, Lei Feng2,3, Yin Bun Cheung5,6, Tze-Pin Ng2,3.   

Abstract

OBJECTIVE: There is no established minimum clinically important difference (MCID) for the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) index and total scale scores. This study aimed to estimate the MCID for the RBANS index scores and total scale score.
METHOD: Participants included 1,856 ethnic Chinese, older adults. Distribution- and anchor-based methods were used to estimate values for the MCID. Distribution-based estimates were calculated as the standard error of measurement (SEM) and .5 standard deviations (SD). For anchor-based estimates, we compared RBANS scores between the clinical dementia rating (CDR) scale no dementia and very mild dementia groups and between the clinical assessment of dementia (CAD) cognitively normal and mild cognitive impairment groups using regression models adjusting for demographic characteristics.
RESULTS: Estimates from the CDR anchor were 7.79, 8.63, 10.74, 9.74, 5.61, and 3.77 for the total scale score, language, immediate memory, delayed memory, visuospatial/constructional, and the attention index, respectively. Estimates from the distribution-based methods were similar to the estimates based on the CDR, except for the language and attention indexes. Estimates from the CAD anchor were larger.
CONCLUSIONS: We estimated the MCID for the total scale score, language, immediate memory, delayed memory, visuospatial/constructional, and attention indexes of the RBANS as 8, 9, 10, 10, 6, and 4 points, respectively. These estimates are best suited to discriminate between patient groups, for example, in a clinical trial setting. Further research is needed using longitudinal data to assess their applicability to assess within patient differences.

Entities:  

Keywords:  Chinese.; Elderly/geriatrics/aging; Mild cognitive impairment; Minimum clinically important difference; Neuropsychological test

Mesh:

Year:  2015        PMID: 26548428     DOI: 10.1080/13854046.2015.1107137

Source DB:  PubMed          Journal:  Clin Neuropsychol        ISSN: 1385-4046            Impact factor:   3.535


  6 in total

1.  Relationship between 18F-Flutemetamol uptake and RBANS performance in non-demented community-dwelling older adults.

Authors:  Dustin B Hammers; Taylor J Atkinson; Bonnie C A Dalley; Kayla R Suhrie; Britney E Beardmore; Lance D Burrell; Kevin P Horn; Kelli M Rasmussen; Norman L Foster; Kevin Duff; John M Hoffman
Journal:  Clin Neuropsychol       Date:  2017-01-12       Impact factor: 3.535

2.  Repeatable battery for the assessment of neuropsychological status and its relationship to biomarkers of Alzheimer's disease.

Authors:  Kevin Duff; Kayla R Suhrie; Dustin B Hammers; Ava M Dixon; Jace B King; Vincent Koppelmans; John M Hoffman
Journal:  Clin Neuropsychol       Date:  2021-10-29       Impact factor: 4.373

3.  Effect of Early High-Dose Vitamin D3 Repletion on Cognitive Outcomes in Critically Ill Adults.

Authors:  Jin H Han; Adit A Ginde; Samuel M Brown; Adrienne Baughman; Erin M Collar; E Wesley Ely; Michelle N Gong; Aluko A Hope; Peter C Hou; Catherine L Hough; Theodore J Iwashyna; James C Jackson; Akram Khan; Onur M Orun; Mayur B Patel; Rameela Raman; Todd W Rice; Nancy Ringwood; Matthew W Semler; Nathan I Shapiro; Daniel S Talmor; Wesley H Self
Journal:  Chest       Date:  2021-04-02       Impact factor: 10.262

4.  Neurocognitive benchmarks following transplant for emerging cerebral adrenoleukodystrophy.

Authors:  Elizabeth I Pierpont; David R Nascene; Ryan Shanley; Daniel L Kenney-Jung; Richard S Ziegler; Weston P Miller; Ashish O Gupta; Troy C Lund; Paul J Orchard; Julie B Eisengart
Journal:  Neurology       Date:  2020-07-02       Impact factor: 9.910

5.  Cognitive Function During Opioid Tapering in Patients with Chronic Pain: A Prospective Cohort Study.

Authors:  Jens Laigaard; Nina Bache; Stefan Stottmeier; Ole Mathiesen; Stine Estrup
Journal:  J Pain Res       Date:  2020-12-14       Impact factor: 3.133

6.  Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer's disease.

Authors:  Edmond Teng; Paul T Manser; Sandra Sanabria Bohorquez; Kristin R Wildsmith; Karen Pickthorn; Suzanne L Baker; Michael Ward; Geoffrey A Kerchner; Robby M Weimer
Journal:  Alzheimers Res Ther       Date:  2021-12-01       Impact factor: 6.982

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.